CompanyTrack
M

MEDIMMUNE LIMITED

Active Cambridge

Other research and experimental development on natural sciences and engineering

202 employees Website
Other research and experimental development on natural sciences and engineering
M

MEDIMMUNE LIMITED

Other research and experimental development on natural sciences and engineering

Founded 11 Dec 1989 Active Cambridge, United Kingdom 202 employees medimmune.com
Other research and experimental development on natural sciences and engineering
Accounts Submitted 7 Aug 2025
Confirmation Statement Submitted 13 Dec 2024
Net assets £-547.00M £1486.00M 2024 year on year
Total assets £2513.00M £620.00M 2024 year on year
Total Liabilities £3060.00M £866.00M 2024 year on year
Charges 5
5 outstanding

AI Analysis

AI Analysis

Analyze director networks, ownership patterns, and company connections

CompanyTrack AI can make mistakes. Check important info.

Contact & Details

Registered Address

1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom

Office (Cambridge)

Milstein Bldg, Granta Park, Cambridge CB21 6GH

Telephone

0122 347 1471

Credit Report

Discover MEDIMMUNE LIMITED's Credit Score, limit, and payment likelihood.

Mutual Companies

Financials

Financials

Period 1 Jan → 31 Dec 2024
Type Total Exemption Full
Next accounts 31 December 2025
Due by 30 September 2026 9 months

Net Assets, Total Assets & Total Liabilities (2014–2024)

Cash in Bank

N/A

Net Assets

-£547.00M

Increased by £1486.00M (+73%)

Total Liabilities

£3060.00M

Decreased by £866.00M (-22%)

Turnover

£2595.00M

Increased by £389.00M (+18%)

Employees

202

Decreased by 29 (-13%)

Debt Ratio

122%

Decreased by 85 (-41%)

Financial History

Revenue, profit, EBITDA and key financial figures

2024
Dec Year End
2023
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

No fundraising or grants recorded

Investors (0)

No investor information available

Share Capital

Share Capital

Share allotments and capital structure

3 Allotments 3 Shares £2139.74m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
25 Mar 20201£334.62m£334.62m
18 Dec 20191£405.11m£405.11m
18 Dec 20171£1400.00m£1400.00m

Officers

Officers

14 active 54 resigned
Status
Alexander De Giorgio-millerDirectorBritishEngland4929 Jun 2024Active
Aradhana SarinDirectorAmericanUnited States5129 Jun 2024Active
Camilla Jane JohnstoneSecretaryUnknownUnknown16 Sept 2019Active
Caterina BrindicciDirectorItalianEngland5029 Jun 2024Active
Christine StephensDirectorBritishEngland5429 Jun 2024Active
Elaine HarropDirectorBritishEngland5129 Jun 2024Active
Hannah Victoria TattersallDirectorBritishEngland381 May 2025Active
Iain Alistair CollinsDirectorBritishUnited Kingdom5531 May 2017Active

Shareholders

Shareholders (1)

Cambridge Antibody Technology Group Limited
100.0%
7,700,02418 Dec 2023

Persons with Significant Control

Persons with Significant Control (1)

1 Active

Cambridge Antibody Technology Group Limited

United Kingdom

Active
Notified 6 Apr 2016
Nature of Control
  • Ownership Of Shares 75 To 100 Percent
  • Voting Rights 75 To 100 Percent
  • Right To Appoint And Remove Directors

Group Structure

Group Structure

CAMBRIDGE ANTIBODY TECHNOLOGY GROUP LIMITED united kingdom shares 75 to 100 percent, appoint/remove directors
ASTRAZENECA TREASURY LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors
ASTRAZENECA UK LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors
ASTRAZENECA INTERMEDIATE HOLDINGS LIMITED united kingdom shares 75 to 100 percent, voting rights 75 to 100 percent, appoint/remove directors
ASTRAZENECA PLC united kingdom
MEDIMMUNE LIMITED Current Company

Charges

Charges

5 outstanding

Documents

Company Filings

DateCategoryDescriptionDocument
7 Aug 2025AccountsAnnual accounts made up to 2024-12-31View(32 pages)
2 May 2025OfficersAppointment of Hannah Victoria Tattersall as director on 2025-05-01View(2 pages)
1 May 2025OfficersTermination of Adrian Charles Noel Kemp as director on 2025-05-01View(1 page)
11 Feb 2025OfficersAppointment of Lutz Jermutus as director on 2025-02-10View(2 pages)
13 Dec 2024Confirmation StatementConfirmation statement made on 2024-12-11 with no updatesView(3 pages)
7 Aug 2025 Accounts

Annual accounts made up to 2024-12-31

2 May 2025 Officers

Appointment of Hannah Victoria Tattersall as director on 2025-05-01

1 May 2025 Officers

Termination of Adrian Charles Noel Kemp as director on 2025-05-01

11 Feb 2025 Officers

Appointment of Lutz Jermutus as director on 2025-02-10

13 Dec 2024 Confirmation Statement

Confirmation statement made on 2024-12-11 with no updates

Recent Activity

Latest Activity

Annual accounts made up to 2024-12-31

6 months ago on 7 Aug 2025

Appointment of Hannah Victoria Tattersall as director on 2025-05-01

9 months ago on 2 May 2025

Termination of Adrian Charles Noel Kemp as director on 2025-05-01

9 months ago on 1 May 2025

Appointment of Lutz Jermutus as director on 2025-02-10

1 years ago on 11 Feb 2025

Confirmation statement made on 2024-12-11 with no updates

1 years ago on 13 Dec 2024